Deutsche Bank Maintains Buy On Regeneron Following Discussion With CEO


In a research report sent to investors today, Deutsche Bank analyst Robyn Karnauskas maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a price target of $455, after she spoke with CEO Leonard Schleifer about dupilumab, Alirocumab and the long-term strategy in regard to the partnership with Sanofi.

Karnauskas briefly noted, “Dupilumab has breakthrough designation and may have anti-asthma activity in both allergic and non-allergic patients, recent positive data from the IMPROVE-IT study supports the LDL-C hypothesis and is supportive for Alirocumab, and the company does not see any strategic difference pre/post the Sanofi partnership set to expire YE17.”

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Robyn Karnauskas has a total average return of 14.0% and a 73.8% success rate. Karnauskas has a 20.7% average return when recommending REGN, and is ranked #139 out of 3391 analysts.